Protein‑degrader startup EpiBiologics raised $107 million in a Series B to advance EPI‑326, a bispecific degrader targeting oncogenic surface proteins, into first‑in‑human studies. The financing was led by GV and Johnson & Johnson’s venture arm and included large strategic life‑science investors. The company, founded by ex‑Genentech leaders and based on work from UCSF, said the funding will support IND filings and early clinical testing in non‑small cell lung cancer and head and neck cancers. Company statements emphasized EPI‑326’s tumor‑selective degradation mechanism and potential for combination with existing targeted agents.